Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 11/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770596 | 0.95 | PRMT5 (0.38) | PRMT5WDR77KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16754293 | 0.95 | PRMT5 (0.38) | PRMT5WDR77KDM4EALDH1A1HSD17B10 | |
| SCHEMBL16754551 | 0.92 | ROCK2 (0.38) | TSHRKDM4EALDH1A1HSD17B10GRM5 | |
| SCHEMBL16754368 | 0.92 | GRM5 (0.39) | TSHRKDM4EALDH1A1HSD17B10GRM5 | |
| SCHEMBL17777142 | 0.92 | GRM5 (0.39) | TSHRKDM4EALDH1A1HSD17B10GRM5 | |
| SCHEMBL16776482 | 0.90 | ALDH1A1 (0.42) | ALDH1A1GRM5MAPTWNT3A | |
| SCHEMBL16754299 | 0.88 | GRM5 (0.37) | TSHRKDM4EALDH1A1HSD17B10GRM5 | |
| SCHEMBL16754281 | 0.87 | JAK2 (0.39) | GRM5 | |
| SCHEMBL17618520 | 0.87 | USP30 (0.37) | GRM5GSK3BWNT3A | |
| SCHEMBL17767975 | 0.87 | WNT3A (0.35) | GRM5WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PRMT5 209/4885WDR77 1434/4885TSHR 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.